Summary
- Pembrolizumab, an immunotherapy drug, targets and destroys cancer cells
- Giving pembrolizumab before surgery led to a significant increase in patients being declared cancer-free
- Patients with a specific genetic profile saw the most benefit from the treatment
- Researchers believe immunotherapy could potentially replace the need for surgery in the future
